BCL2L1 and metastatic neoplasm: Consistent with these findings, immunohistochemical analysis of BCL-2, BAX, BCL-XL, and MCL-1 in primary low grade and advanced grade prostate tumors showed similar patterns with substantial increase in MCL-1 and BclXL immunoreactivity in high grade metastatic tumors and modest increase in BCL-2, while no significant changes were reported for BAX [84].